Apolipoprotein E gene is related to mortality only in normal weight individuals: The Rotterdam study

European Journal of Epidemiology

Volumn 23, Issue 2, 2008, Pages 135-142

  Pardo Silva, M Carolina ^a   Janssens, A Cecile J W ^a   Hofman, Albert ^a   Witteman, Jacqueline C M ^a   Van Duijn, Cornelia M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

APOE; BMI; CHD mortality; Cholesterol; Mortality

Indexed keywords

APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GENOTYPE; HOMOZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBESITY; POPULATION RESEARCH;

AGED; APOLIPOPROTEINS E; BODY MASS INDEX; BODY WEIGHT; CORONARY DISEASE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MORTALITY; NETHERLANDS; RISK; SAFETY MANAGEMENT;

EID: 38649084428     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-007-9202-6     Document Type: Article

References (39)

1. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol 2002;155:487-95.
2. Horejsi B, Ceska R. Apolipoproteins and atherosclerosis. Apolipoprotein E and apolipoprotein(a) as candidate genes of premature development of atherosclerosis. Physiol Res 2000;49(Suppl 1):S63-9.
3. Ilveskoski E, Loimaala A, Mercuri MF, Lehtimaki T, Pasanen M, Nenonen A, Oja P, Bond MG, Koivula T, Karhunen PJ, Vuori I. Apolipoprotein E polymorphism and carotid artery intima-media thickness in a random sample of middle-aged men. Atherosclerosis 2000;153:147-53.
4. Davignon J. Apolipoprotein E and atherosclerosis: beyond lipid effect. Arterioscler Thromb Vasc Biol 2005;25:267-9.
5. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 2004;141:137-47.
6. Lee JH, Tang MX, Schupf N, Stern Y, Jacobs DM, Tycko B, Mayeux R. Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet 2001;103:121-7.
7. Raiha I, Marniemi J, Puukka P, Toikka T, Ehnholm C, Sourander L. Effect of serum lipids, lipoproteins, and apolipoproteins on vascular and nonvascular mortality in the elderly. Arterioscler Thromb Vasc Biol 1997;17:1224-32.
8. Vogt MT, Cauley JA, Kuller LH. Apolipoprotein E phenotype, arterial disease, and mortality among older women: the study of osteoporotic fractures. Genet Epidemiol 1997;14:147-56.
9. Stengard JH, Zerba KE, Pekkanen J, Ehnholm C, Nissinen A, Sing CF. Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation 1995;91:265-9.
10. Tilvis RS, Kahonen-Vare MH, Jolkkonen J, Valvanne J, Pitkala KH, Strandberg TE. Predictors of cognitive decline and mortality of aged people over a 10-year period. J Gerontol A Biol Sci Med Sci 2004;59:268-74.
11. Hayden KM, Zandi PP, Lyketsos CG, Tschanz JT, Norton MC, Khachaturian AS, Pieper CF, Welsh-Bohmer KA, Breitner JC. Apolipoprotein E genotype and mortality: findings from the Cache County Study. J Am Geriatr Soc 2005;53:935-42.
12. Slooter AJ, Cruts M, Van Broeckhoven C, Hofman A, van Duijn CM. Apolipoprotein E and longevity: the Rotterdam Study. J Am Geriatr Soc 2001;49:1258-9.
13. Kuusisto J, Mykkanen L, Kervinen K, Kesaniemi YA, Laakso M. Apolipoprotein E4 phenotype is not an important risk factor for coronary heart disease or stroke in elderly subjects. Arterioscler Thromb Vasc Biol 1995;15:1280-6.
14. Koivisto AM, Lempiainen P, Koivisto K, Helkala EL, Mykkanen L, Kuusisto J, Kervinen K, Kesaniemi YA, Laakso M, Soininen H. Apolipoprotein E phenotype alone does not influence survival in Alzheimer's disease: a population-based longitudinal study. Neuroepidemiology 2000;19:327-32.
15. Heijmans BT, Slagboom PE, Gussekloo J, Droog S, Lagaay AM, Kluft C, Knook DL, Westendorp RG. Association of APOE epsilon2/epsilon3/epsilon4 and promoter gene variants with dementia but not cardiovascular mortality in old age. Am J Med Genet 2002;107:201-8.
16. Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, Sulkava R. APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 2000;54:412-5.
17. Skoog I, Hesse C, Aevarsson O, Landahl S, Wahlstrom J, Fredman P, Blennow K. A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry 1998;64:37-43.
18. Fillenbaum GG, Burchett BM, Lee JH, Blazer DG. Mortality, apolipoprotein E in African-American, and White elders: an attempted replication. Am J Med Genet 2003;119A:141-6.
19. Schupf N, Costa R, Luchsinger J, Tang MX, Lee JH, Mayeux R. Relationship between plasma lipids and all-cause mortality in nondemented elderly. J Am Geriatr Soc 2005;53:219-26.
20. Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, Hanaire-Broutin H, Perret B, Ferrieres J. Obesity and alcohol modulate the effect of apolipoprotein E polymorphism on lipids and insulin. Obes Res 2003;11:1200-6.
21. Srinivasan SR, Ehnholm C, Elkasabany A, Berenson GS. Apolipoprotein E polymorphism modulates the association between obesity and dyslipidemias during young adulthood: the Bogalusa Heart Study. Metabolism 2001;50:696-702.
22. Boer JM, Ehnholm C, Menzel HJ, Havekes LM, Rosseneu M, O'Reilly DS, Tiret L. Interactions between lifestyle-related factors and the ApoE polymorphism on plasma lipids and apolipoproteins. The EARS Study. European Atherosclerosis Research Study. Arterioscler Thromb Vasc Biol 1997;17:1675-81.
23. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991;7:403-22.
24. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000;894:i-xii, 1-253.
25. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. J Hypertens 1999;17:151-83.
26. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26 Suppl 1:S5-20.
27. van Gent CM, van der Voort HA, de Bruyn AM, Klein F. Cholesterol determinations. A comparative study of methods with special reference to enzymatic procedures. Clin Chim Acta 1977;75:243-51.
28. Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
29. Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, Cruts M, Van Broeckhoven C, Breteler MM, Hofman A, Stijnen T, van Duijn CM. Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999;246(4):304-8.
30. WHO. International Statistical classification of diseases and related health problems. Geneva: World Health Organization; 1992.
31. Cheung YB, Gao F, Khoo KS. Age at diagnosis and the choice of survival analysis methods in cancer epidemiology. J Clin Epidemiol 2003;56:38-43.
32. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80.
33. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982;69:239-41.
34. Schachter F, Faure-Delanef L, Guenot F, Rouger H, Froguel P, Lesueur-Ginot L, Cohen D. Genetic associations with human longevity at the APOE and ACE loci. Nat Genet 1994;6:29-32.
35. Christensen K, Johnson TE, Vaupel JW. The quest for genetic determinants of human longevity: challenges and insights. Nat Rev Genet 2006;7:436-48.
36. Bathum L, Christiansen L, Jeune B, Vaupel J, McGue M, Christensen K. Apolipoprotein E genotypes: relationship to cognitive functioning, cognitive decline, and survival in nonagenarians. J Am Geriatr Soc 2006;54:654-8.
37. Pouliot MC, Despres JP, Moorjani S, Lupien PJ, Tremblay A, Bouchard C. Apolipoprotein E polymorphism alters the association between body fatness and plasma lipoproteins in women. J Lipid Res 1990;31:1023-9.
38. de Beer F, Stalenhoef AF, Hoogerbrugge N, Kastelein JJ, Gevers Leuven JA, van Duijn CM, Havekes LM, Smelt AH. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158 → Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 2002;22:294-9.
39. Mahley RW, Huang Y, Rall SC Jr. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. J Lipid Res 1999;40:1933-49.